用于质瘤免疫治疗的CSF1R抑制剂C19,通过针对大脑的脂质体输送激活
Wen-Qin Song1,2, Yue-Qian Wu2,3, Quan-Feng Zhu4
1Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Acta pharmacologica Sinica
|February 6, 2026
概括
一种新的脂质体输送系统 (T12-Lipo) 有效地通过血脑屏障传递殖民地刺激因子1受体 (CSF1R) 抑制剂. 这通过重编程与瘤相关的巨细胞和促进T细胞反应来增强质瘤的免疫疗法.
科学领域:
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
- 药物运输 药物运输 药物运输
背景情况:
- 用殖民地刺激因子1受体 (CSF1R) 抑制剂向瘤相关巨细胞 (TAMs) 对质瘤免疫治疗有希望.
- 之前的CSF1R抑制剂面临的挑战是由于血脑屏障 (BBB) 穿透不良.
研究的目的:
- 开发一种针对大脑的CSF1R抑制剂的输送系统,以克服质瘤治疗中的BBB限制.
- 为了提高TAM向性免疫治疗质瘤的疗效.
主要方法:
- 开发T12-脂质体 (T12-Lipo),用T12进行转移林受体结合.
- 使用T12-Lipo将CSF1R抑制剂C19传递到BBB和TAM中.
- 在质瘤模型中评估TAM再极化,T细胞激活和治疗疗效.
主要成果:
- T12-Lipo证明了在BBB和TAM中增强了C19的传递.
- 该系统促进了TAM再极化到一种类似M1的抗瘤表型.
- 观察到针对质瘤生长的显著疗效,与改善的T细胞中介杀死有关.
结论:
- 针对大脑的C19的T12-Lipo配方是质瘤免疫治疗的有希望的策略.
- 这种方法有效地克服了BBB的局限性,调节瘤微环境,并增强了抗质瘤免疫反应.
相关概念视频
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors
686
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
686
Antihypertensive Drugs: Direct Renin Inhibitors
1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615


